Galectin Therapeutics Appoints Industry Veteran Rex Horton As Executive Director Of Regulatory Affairs And Quality Assurance
Galectin Therapeutics Inc. (NASDAQ: GALT), the leading developer of
therapeutics that target galectin proteins to treat fibrosis and cancer,
today announced the appointment of Rex Horton as Executive Director of
Galectin Therapeutics Inc. (NASDAQ: GALT), the leading developer of therapeutics that target galectin proteins to treat fibrosis and cancer, today announced the appointment of Rex Horton as Executive Director of Regulatory Affairs and Quality Assurance. Mr. Horton is an experienced industry professional with 20 years of management and leadership experience in global regulatory affairs matters including drugs, biologics and vaccines. “Rex Horton has broad range of regulatory affairs and quality leadership experience that is directly relevant to Galectin Therapeutics development programs, with expertise spanning preclinical development through new drug approvals in diverse therapeutic areas, including gastroenterology,” said Peter G. Traber, MD, President, Chief Executive Officer and Chief Medical Officer of Galectin. “Rex joins us at an auspicious time in the Company’s history as we are poised to submit an IND for GR-MD-02 for treatment of non-alcoholic steatohepatitis (NASH) with fibrosis and expect to initiate a Phase 1 clinical trial early this year. I am therefore glad to welcome Rex to our team and expect that he will make significant contributions to Galectin Therapeutics as we continue to develop a treatment with the promise to effectively treat these common and deadly disorders.” “I am extremely pleased to be joining Galectin Therapeutics at a pivotal stage in the development of its novel carbohydrate compounds for the treatment of fibrotic disease and cancer,” added Mr. Horton. “The Company has extensive scientific and development expertise within its organization, and I am impressed by the balanced strategic vision of the leadership team, which has a clear long-term focus on developing galectin inhibitors for these serious and life-threatening indications where significant unmet medical needs still exist.” Mr. Horton most recently was Director of Regulatory Affairs at Chelsea Therapeutics, where he successfully led the organization through its first NDA filing and favorable FDA Advisory Committee Meeting. In past leadership roles at Solvay Pharmaceuticals and Abbott Laboratories, he led approval efforts for key products including Androgel® Stickpack, Creon® Capsules and Luvox® CR Capsules. He has also provided chemistry, manufacturing and controls (CMC) regulatory leadership and support of INDs and NDAs, including Estrogel® and Androgel® Pump. Mr. Horton was a member of the executive leadership team that successfully implemented solutions to significant regulatory issues encountered by Solvay in its interactions with the FDA.
Motorcar Parts of America, Inc. (NASDAQ:MPAA), Galectin Therapeutics Inc. (NASDAQ:GALT) and Town Sports International Holdings, Inc. (NASDAQ:CLUB) started off this Wednesday strong and are among the...